Published in J Biol Chem on January 31, 2011
EGFR and HER2 receptor kinase signaling mediate epithelial cell invasion by Candida albicans during oropharyngeal infection. Proc Natl Acad Sci U S A (2012) 1.81
Quantitative tomographic imaging of intermolecular FRET in small animals. Biomed Opt Express (2012) 1.10
Near infrared photoimmunotherapy in the treatment of disseminated peritoneal ovarian cancer. Mol Cancer Ther (2014) 1.01
Synbindin in extracellular signal-regulated protein kinase spatial regulation and gastric cancer aggressiveness. J Natl Cancer Inst (2013) 1.01
Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization. Cancer Res (2013) 1.00
Rapid ratiometric biomarker detection with topically applied SERS nanoparticles. Technology (Singap World Sci) (2014) 0.93
Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation. Neoplasia (2013) 0.93
Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer. ISRN Oncol (2012) 0.92
Model-based global sensitivity analysis as applied to identification of anti-cancer drug targets and biomarkers of drug resistance in the ErbB2/3 network. Eur J Pharm Sci (2011) 0.91
Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy. Oncogene (2013) 0.89
HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models. Oncotarget (2014) 0.84
In vivo multiplexed molecular imaging of esophageal cancer via spectral endoscopy of topically applied SERS nanoparticles. Biomed Opt Express (2015) 0.84
Quantification of HER expression and dimerization in patients' tumor samples using time-resolved Förster resonance energy transfer. PLoS One (2012) 0.83
Biophysical Detection of Diversity and Bias in GPCR Function. Front Endocrinol (Lausanne) (2014) 0.82
Deconstructing signaling in three dimensions. Biochemistry (2014) 0.81
Homogeneous time-resolved fluorescence-based assay to monitor extracellular signal-regulated kinase signaling in a high-throughput format. Front Endocrinol (Lausanne) (2014) 0.79
Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (1975) 83.56
Untangling the ErbB signalling network. Nat Rev Mol Cell Biol (2001) 28.05
ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer (2005) 16.73
A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol (2008) 14.74
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol (2005) 8.08
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell (2004) 6.12
Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell (2009) 6.02
Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell (2002) 4.92
ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol (2009) 4.40
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell (2002) 4.34
Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene (2008) 2.72
Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol (2003) 2.65
The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res (2004) 2.64
Ligand-induced dimer-tetramer transition during the activation of the cell surface epidermal growth factor receptor-A multidimensional microscopy analysis. J Biol Chem (2005) 2.54
EGFR signaling and drug discovery. Oncology (2010) 2.53
Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother (2005) 1.98
EGFR family: structure physiology signalling and therapeutic targets. Growth Factors (2008) 1.87
Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2. J Biol Chem (1996) 1.87
EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol (2002) 1.86
Coregulation of epidermal growth factor receptor/human epidermal growth factor receptor 2 (HER2) levels and locations: quantitative analysis of HER2 overexpression effects. Cancer Res (2003) 1.80
Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim Biophys Acta (2008) 1.76
Endocytosis deficiency of epidermal growth factor (EGF) receptor-ErbB2 heterodimers in response to EGF stimulation. Mol Biol Cell (1999) 1.74
Localization of a major receptor-binding domain for epidermal growth factor by affinity labeling. Mol Cell Biol (1988) 1.67
Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol (2004) 1.64
Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol (2004) 1.58
Monoclonal antibodies against the extracellular domain of the erbB-2 receptor function as partial ligand agonists. J Biol Chem (1992) 1.58
A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue. Diagn Mol Pathol (2009) 1.50
Modulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rare. J Clin Oncol (2004) 1.48
ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib. Cancer Biol Ther (2007) 1.43
Cell surface detection of membrane protein interaction with homogeneous time-resolved fluorescence resonance energy transfer technology. Anal Biochem (2004) 1.40
Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site. J Biol Chem (1997) 1.38
In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas. Clin Cancer Res (2007) 1.35
The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 increases the formation of inactive untethered EGFR dimers. Implications for combination therapy with monoclonal antibody 806. J Biol Chem (2006) 1.30
Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3. Biochem Biophys Res Commun (2000) 1.29
c-erbB-2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells. FASEB J (1999) 1.27
HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation. Cancer Res (2010) 1.13
Interaction of antibodies with ErbB receptor extracellular regions. Exp Cell Res (2008) 1.13
2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth. Cancer (2005) 1.12
Flow cytometric FRET analysis of erbB receptor interaction on a cell-by-cell basis. Ann N Y Acad Sci (2008) 1.05
Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerization. Mol Cancer Ther (2009) 1.03
Kinase-mediated quasi-dimers of EGFR. FASEB J (2010) 1.01
A proximity ligation assay using transiently transfected, epitope-tagged proteins: application for in situ detection of dimerized receptor tyrosine kinases. Biotechniques (2010) 1.00
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action? J Cell Physiol (2003) 1.00
Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling. Mol Cancer Ther (2007) 0.99
Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation. Int J Oncol (2009) 0.99
Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts. Ann Oncol (2009) 0.99
Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185her2/neu and the EGFR-p185her2/neu complexes. Oncogene (2008) 0.99
Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments. Histopathology (2010) 0.87
Targeted antireceptor therapy with monoclonal antibodies leads to the formation of inactivated tetrameric forms of ErbB receptors. J Immunol (2007) 0.84
Effect of ErbB2 coexpression on the kinetic interactions of epidermal growth factor with its receptor in intact cells. Biochemistry (2002) 0.83
HER-dimerization inhibitors: evaluating pertuzumab in women's cancers. Expert Opin Biol Ther (2010) 0.82
Microbead arrays for the analysis of ErbB receptor tyrosine kinase activation and dimerization in breast cancer cells. Assay Drug Dev Technol (2010) 0.79
Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol (2010) 7.29
Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol (2012) 2.92
Cell-surface protein-protein interaction analysis with time-resolved FRET and snap-tag technologies: application to GPCR oligomerization. Nat Methods (2008) 2.88
Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network. Lancet Oncol (2006) 2.32
Time-resolved FRET between GPCR ligands reveals oligomers in native tissues. Nat Chem Biol (2010) 2.15
Impact of RNA degradation on gene expression profiles: assessment of different methods to reliably determine RNA quality. J Biotechnol (2006) 2.12
Phyllodes tumor of the breast. Int J Radiat Oncol Biol Phys (2007) 2.02
Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol (2009) 1.94
Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol (2011) 1.78
Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol (2012) 1.74
Intraoperative radiotherapy in early-stage breast cancer: results of the montpellier phase II trial. Int J Radiat Oncol Biol Phys (2009) 1.69
Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol (2010) 1.68
Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol (2010) 1.65
Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. J Clin Oncol (2007) 1.63
Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional and IMRT plans. Radiat Oncol (2007) 1.60
Concurrent administration of adjuvant chemotherapy and radiotherapy after breast-conserving surgery enhances late toxicities: long-term results of the ARCOSEIN multicenter randomized study. Int J Radiat Oncol Biol Phys (2006) 1.60
Cell-penetrating and cell-targeting peptides in drug delivery. Biochim Biophys Acta (2008) 1.54
Brief intraperitoneal radioimmunotherapy of small peritoneal carcinomatosis using high activities of noninternalizing 125I-labeled monoclonal antibodies. J Nucl Med (2010) 1.45
Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy. Arch Otolaryngol Head Neck Surg (2006) 1.42
Cell surface detection of membrane protein interaction with homogeneous time-resolved fluorescence resonance energy transfer technology. Anal Biochem (2004) 1.40
[White paper on radiation oncology in France. Twelve proposals to improve a major cancer treatment. Société française de radiothérapie oncologique]. Cancer Radiother (2013) 1.39
In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas. Clin Cancer Res (2007) 1.35
CD4 and CD8 T-lymphocyte apoptosis can predict radiation-induced late toxicity: a prospective study in 399 patients. Clin Cancer Res (2005) 1.32
Single nucleotide polymorphisms, apoptosis, and the development of severe late adverse effects after radiotherapy. Clin Cancer Res (2008) 1.30
Plan comparison of volumetric-modulated arc therapy (RapidArc) and conventional intensity-modulated radiation therapy (IMRT) in anal canal cancer. Radiat Oncol (2010) 1.25
Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women. Clin Cancer Res (2009) 1.23
Establishment of a Radiogenomics Consortium. Int J Radiat Oncol Biol Phys (2010) 1.23
Overexpression of phosphoserine aminotransferase PSAT1 stimulates cell growth and increases chemoresistance of colon cancer cells. Mol Cancer (2008) 1.22
Radiotherapy technical considerations in the management of locally advanced pancreatic cancer: American-French consensus recommendations. Int J Radiat Oncol Biol Phys (2012) 1.20
MR volumetric measurement of low rectal cancer helps predict tumor response and outcome after combined chemotherapy and radiation therapy. Radiology (2012) 1.18
KRAS mutation detection in paired frozen and Formalin-Fixed Paraffin-Embedded (FFPE) colorectal cancer tissues. Int J Mol Sci (2011) 1.17
The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications. Radiat Oncol (2006) 1.13
Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment. Radiat Oncol (2012) 1.12
Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation (2002) 1.12
Anti-HER2 vaccines: new prospects for breast cancer therapy. Cancer Immunol Immunother (2010) 1.12
Prognostic significance of TRIM24/TIF-1α gene expression in breast cancer. Am J Pathol (2011) 1.12
D-myo-inositol 1-phosphate as a surrogate of D-myo-inositol 1,4,5-tris phosphate to monitor G protein-coupled receptor activation. Anal Biochem (2006) 1.11
Clinical radioimmunotherapy--the role of radiobiology. Nat Rev Clin Oncol (2011) 1.10
Genetic predictors of adverse radiotherapy effects: the Gene-PARE project. Int J Radiat Oncol Biol Phys (2006) 1.10
Outcome and prognostic factors in olfactory neuroblastoma: a rare cancer network study. Int J Radiat Oncol Biol Phys (2010) 1.08
Identification and characterization of tumor antigens by using antibody phage display and intrabody strategies. Mol Immunol (2007) 1.07
Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers. Breast Cancer Res (2011) 1.06
Intraoperative radiotherapy given as a boost for early breast cancer: long-term clinical and cosmetic results. Int J Radiat Oncol Biol Phys (2006) 1.02
Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands. J Med Chem (2007) 1.02
Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization? Qual Life Res (2013) 1.01
Letrozole sensitizes breast cancer cells to ionizing radiation. Breast Cancer Res (2004) 1.01
Quality of life assessment after concurrent chemoradiation for invasive bladder cancer: results of a multicenter prospective study (GETUG 97-015). Int J Radiat Oncol Biol Phys (2010) 1.00
Cell membrane is a more sensitive target than cytoplasm to dense ionization produced by auger electrons. Radiat Res (2008) 1.00
Reverse transcription-quantitative polymerase chain reaction: description of a RIN-based algorithm for accurate data normalization. BMC Mol Biol (2009) 0.99
Anal canal cancer: management of inguinal nodes and benefit of prophylactic inguinal irradiation (CORS-03 Study). Int J Radiat Oncol Biol Phys (2011) 0.98
Prognostic impact of epidermal growth factor receptor (EGFR) expression on loco-regional recurrence after preoperative radiotherapy in rectal cancer. BMC Cancer (2005) 0.98
MHC class I-related chain A conjugated to antitumor antibodies can sensitize tumor cells to specific lysis by natural killer cells. Clin Cancer Res (2005) 0.97
Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial. J Clin Oncol (2007) 0.96
Diagnosis and management of anaemia and iron deficiency in patients with haematological malignancies or solid tumours in France in 2009-2010: the AnemOnHe study. Eur J Cancer (2011) 0.96
Optimal timing for adjuvant radiation therapy in breast cancer: a comprehensive review and perspectives. Crit Rev Oncol Hematol (2008) 0.94
Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation. Neoplasia (2013) 0.93
Assessment of epidermal growth factor receptor (EGFR) expression in primary colorectal carcinomas and their related metastases on tissue sections and tissue microarray. Virchows Arch (2006) 0.93
Application of the Spot method to the identification of peptides and amino acids from the antibody paratope that contribute to antigen binding. J Immunol Methods (2002) 0.93
Proteomic approaches to identify biomarkers predictive of radiotherapy outcomes. Expert Rev Proteomics (2013) 0.93
IMRT for locally advanced anal cancer: clinical experience of the Montpellier Cancer Center. Radiat Oncol (2012) 0.93
Neoadjuvant chemoradiotherapy in esophageal cancer: is it still the question? J Clin Oncol (2008) 0.92
A homogeneous time-resolved fluorescence detection of telomerase activity. Anal Biochem (2004) 0.92
R-Cadherin expression inhibits myogenesis and induces myoblast transformation via Rac1 GTPase. Cancer Res (2008) 0.92
Llama single-domain antibodies directed against nonconventional epitopes of tumor-associated carcinoembryonic antigen absent from nonspecific cross-reacting antigen. FEBS J (2009) 0.92
The aberrant localization of oncogenic kit tyrosine kinase receptor mutants is reversed on specific inhibitory treatment. Mol Cancer Res (2009) 0.92
Novel therapeutic strategies combining antihormonal and biological targeted therapies in breast cancer: focus on clinical trials and perspectives. Crit Rev Oncol Hematol (2007) 0.92
Noninternalizing monoclonal antibodies are suitable candidates for 125I radioimmunotherapy of small-volume peritoneal carcinomatosis. J Nucl Med (2009) 0.91
Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN). Gynecol Oncol (2007) 0.91
Eight years of IMRT quality assurance with ionization chambers and film dosimetry: experience of the Montpellier Comprehensive Cancer Center. Radiat Oncol (2011) 0.90
New concept for immediate breast reconstruction for invasive cancers: feasibility, oncological safety and esthetic outcome of post-neoadjuvant therapy immediate breast reconstruction versus delayed breast reconstruction: a prospective pilot study. Breast Cancer Res Treat (2010) 0.90
General overview of radioimmunotherapy of solid tumors. Immunotherapy (2013) 0.89
Luminescent lanthanide cryptates: from the bench to the bedside. Inorg Chem (2014) 0.89
Identification and validation of new autoantibodies for the diagnosis of DCIS and node negative early-stage breast cancers. Int J Cancer (2012) 0.89
Fluorescence technologies for the investigation of chemical libraries. Mol Biosyst (2006) 0.89
EGFR and HER3 mRNA expression levels predict distant metastases in locally advanced rectal cancer. Int J Cancer (2010) 0.88
Prevalence and treatment management of oropharyngeal candidiasis in cancer patients: results of the French CANDIDOSCOPE study. Int J Radiat Oncol Biol Phys (2010) 0.88
Guidelines for equipment and staffing of radiotherapy facilities in the European countries: final results of the ESTRO-HERO survey. Radiother Oncol (2014) 0.88
Localization of the discontinuous immunodominant region recognized by human anti-thyroperoxidase autoantibodies in autoimmune thyroid diseases. J Biol Chem (2002) 0.88
Serum autoantibody signature of ductal carcinoma in situ progression to invasive breast cancer. Clin Cancer Res (2012) 0.87
Persistently better treatment planning results of intensity-modulated (IMRT) over conformal radiotherapy (3D-CRT) in prostate cancer patients with significant variation of clinical target volume and/or organs-at-risk. Radiother Oncol (2008) 0.87
Single-domain antibody-based and linker-free bispecific antibodies targeting FcγRIII induce potent antitumor activity without recruiting regulatory T cells. Mol Cancer Ther (2013) 0.87
Detection of anti-p53 antibodies by ELISA using p53 synthetic or phage-displayed peptides. J Immunol Methods (2002) 0.87